查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011726

动物用药品活性成分市场：依动物种类、产品类型、化合物类型、原料、应用及最终用户划分－2026-2032年全球市场预测

Animal Health Active Pharmaceutical Ingredients Market by Animal Type, Product Type, Compound Type, Source, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，动物用药品活性成分市场价值将达到 203.9 亿美元，到 2026 年将成长至 220.3 亿美元，到 2032 年将达到 360.8 亿美元，复合年增长率为 8.49%。

主要市场统计数据
基准年 2025 203.9亿美元
预计年份：2026年 220.3亿美元
预测年份 2032 360.8亿美元
复合年增长率 (%) 8.49%

对动物用药品成分 (API) 产业进行全面分析，重点在于科学创新、监管现实以及影响策略选择的供应链复杂性。

原料药（API）是动物用药品的基础，它处于科学创新、监管和复杂的全球供应链的交汇点。本导言概述了重塑该领域的关键驱动因素——即对高价值生物製药和肽类药物日益增长的需求、对合理使用抗菌药物（AMS）的审查力度加大、给药途径偏好的转变以及采购中对永续性和可追溯性的日益重视——为本报告提供背景。这些趋势与原材料供应和物流持续面临的压力同时发生，因此，全面考虑这些因素需要采取更细緻入微的产品开发和采购方法。

对科学、营运和商业领域中正在重塑动物用药品活性成分 (API) 竞争和生产方法的交叉因素进行分析。

动物用药品原料药（API）产业正经历一系列变革，这些变革正在改变竞争格局并调整投资重点。首先，治疗重点正转向标靶性强、物种特异性的介入措施。生物製药和胜肽类药物正在扩大其在伴侣动物和高价值牲畜中的治疗应用范围，而合理使用抗生素的计划正在推动製剂的重新设计和非抗生素替代品的开发。这些科学变革需要新的生产能力、更强大的低温运输物流以及研发团队和生产团队之间更紧密的合作。

对近期关税措施对动物用药品原料药整个价值链的采购成本、供应商选择和合规负担带来的实质变化检验。

近期关税措施和贸易政策调整为动物用药品药的采购、生产和分销环节的相关人员带来了更大的复杂性。关税不仅透过对成品原料药和中间体征收直接进口关税影响成本结构，还透过改变生物製药和胜肽类药物生产所需的原料、特殊试剂和资本设备的采购经济性而产生影响。为此，各组织正在审查供应商合同，探索近岸外包方案，并重新评估总到岸成本模型，以维持获利能力和供应的连续性。

将动物种类、治疗领域、化合物类别、给药途径和来源与开发和供应链要求联繫起来的详细細項分析。

细分市场洞察揭示了科学创新、监管重点和商业性需求之间的交集，从而在整个动物用药品药市场创造了差异化的机会。根据动物种类，水产养殖、伴侣动物、牲畜和家禽的市场需求驱动因素和产品开发重点有显着差异。伴侣动物产业通常领先采用尖端生物製药，而水产养殖业则需要能够耐受水生环境的製剂。根据产品类型，治疗产品组合包括抗发炎药物、抗生素、驱虫药、荷尔蒙和疫苗，每个类别都面临独特的生产和监管挑战。疫苗和驱虫药通常需要完善的低温运输和稳定性策略，而小分子抗生素则更注重成本效益高的合成路线和合理的使用方案。

进行策略性区域评估，比较和对比各区域的监管成熟度、生产能力和商业化趋势，并利用该评估进行在地化。

区域趋势在动物用药品产业的筹资策略、监管预期和商业性应用方面发挥着至关重要的作用。美洲地区拥有成熟的法规环境和先进的生产能力，同时对伴侣动物和特殊牲畜应用领域的高价值治疗药物有着强烈的需求。该地区的市场参与企业，在完善的临床试验基础设施和成熟的低温运输物流的支持下，日益专注于生物製药和胜肽类药物的创新，同时也关注供应链安全和关税相关的成本问题。

评估企业策略、能力专业化和协作模式如何重塑 API 生态系统内的竞争优势和伙伴关係。

企业层面的发展趋势正透过策略投资、能力专业化以及贯穿整个价值链的协作而重塑。主要企业和专业合约研发生产机构（CDMO）正透过专注于特定能力群聚（例如生物製药製程开发、胜肽合成规模化或复杂吸入装置的整合）来满足特定的临床和商业性需求，从而实现差异化竞争。这些能力丛集提高了仿製药企业的进入门槛，同时也为缺乏内部专业知识的企业创造了合作机会。

为高阶主管提供实用指南，以增强动物用药品药产业的韧性，加速生物製药和胜肽类药物能力的发展，并优化采购和监管合规性。

产业领导企业应务实地将策略投资与营运调整结合，从而将风险转化为机会。首先，应实现供应商网路多元化，并为关键中间体和特殊试剂建立区域冗余，以降低单点故障和关税波动带来的风险。对高优先级原料进行双重采购和近岸外包投资，既能保障业务永续营运，又能确保在需要更换供应商时能够快速回应监管要求。其次，应将资金投入生物製药和胜肽产品的生产能力建设中，因为科学和商业性征兆均显示这些领域的需求持续强劲。结合策略伙伴关係关係，这可以缩短产品上市时间，并利用外部专业知识，而无需过度扩张内部资源。

透明的调查方法结合了第一手访谈、二手文献和三角检验，从而得出可靠且可操作的产业见解。

本分析所依据的研究透过结合一手定性研究结果和全面的二手数据，确保了其可靠性和相关性。一手资料包括对相关人员的结构化访谈，这些利害关係人包括製药科学家、生产经理、采购负责人、兽医临床专家和监管专家。透过这些对话，我们获得了关于供应链限制因素、技术应用以及不同动物物种和给药途径下未满足需求的实地观点。在条件允许的情况下，我们与多个相关人员群体进行了交叉检验，以协调不同的观点并识别一致的趋势。

对决定不断变化的动物用药品原料药(API) 市场成功与否的策略挑战和营运重点进行简洁的整合。

整体情况，我们看到的是一个正在变革时期的行业，科学进步、监管变革和供应链现实相互交织，重新定义了策略重点。生物製剂和胜肽类药物正在重塑治疗方案，而小分子化合物在关键适应症中仍发挥核心作用。给药途径的选择和原材料的来源必须被视为产品策略的组成部分，而非事后考虑的因素，因为它们会显着影响生产的复杂性、监管要求和市场接受度。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：动物用药品活性成分市场：依动物类型划分

  • 水产养殖
  • 伴侣动物
  • 家畜
  • 家禽

第九章：动物用药品活性成分市场：依产品类型划分

  • 抗发炎药
  • 抗生素
  • 驱虫
  • 荷尔蒙
  • 疫苗

第十章：动物用药品活性成分市场（依化合物类型划分）

  • 生物製药
  • 胜肽
  • 低分子化合物

第十一章：动物用药品活性成分市场：依来源划分

  • 发酵衍生的
  • 天然萃取物
  • 合成

第十二章：动物用药品活性成分市场：依应用领域划分

  • 感染疾病控制
  • 疼痛管理
  • 寄生虫控制
  • 免疫支持
  • 生殖健康
  • 慢性病治疗

第十三章：动物用药品活性成分市场：依最终用户划分

  • 饲料生产商
  • 製药公司
  • 契约製造组织（CMO）

第十四章：动物用药品活性成分市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：动物用药品活性成分市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：动物用药品活性成分市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国动物用药品活性成分市场

第十八章：中国动物用药品活性成分市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alivira Animal Health Limited
  • Ashish Life Science Pvt. Ltd.
  • Aurobindo Pharma Ltd.
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Cipla Ltd.
  • Elanco Animal Health Incorporated
  • Hikal Ltd.
  • Huvepharma Inc.
  • Karishma Pharma Pvt. Ltd.
  • Menon Animal Health
  • Merck & Co., Inc.
  • NGL Fine-Chem Ltd.
  • Phibro Animal Health Corporation
  • Ridgeway Biologicals Ltd.
  • Sequent Scientific Ltd.
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
  • Zydus Animal Health and Investments Ltd.
Product Code: MRR-430D3EB72270

The Animal Health Active Pharmaceutical Ingredients Market was valued at USD 20.39 billion in 2025 and is projected to grow to USD 22.03 billion in 2026, with a CAGR of 8.49%, reaching USD 36.08 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.39 billion
Estimated Year [2026] USD 22.03 billion
Forecast Year [2032] USD 36.08 billion
CAGR (%) 8.49%

Comprehensive framing of the animal health API arena emphasizing scientific innovation, regulatory realities, and supply chain complexity shaping strategic choices

The active pharmaceutical ingredients (APIs) that underpin animal health therapeutics are at the intersection of scientific innovation, regulatory oversight, and complex global supply chains. This introduction sets the stage by outlining the principal drivers reshaping the sector: rising demand for higher-value biologics and peptides, heightened scrutiny around antimicrobial stewardship, evolving route-of-administration preferences, and the increasing emphasis on sustainability and traceability in sourcing. These dynamics are occurring alongside persistent pressures on raw material availability and logistics, which together require a more nuanced approach to product development and procurement.

As innovation accelerates, the industry is witnessing a diversification of compound types and delivery systems. Biologic APIs are expanding therapeutic possibilities but also demand significant investments in manufacturing capability and cold-chain logistics. At the same time, small molecules remain essential for many core indications, and peptides offer a middle path that combines specificity with manufacturing improvements. Regulatory frameworks continue to adapt to these shifts, emphasizing quality-by-design, pharmacovigilance, and explicit requirements for data supporting safety in target species. Consequently, organizations must align scientific strategy with compliance roadmaps early in development to avoid downstream delays.

Supply chain considerations are equally central to strategic planning. The sourcing profile of APIs-whether fermentation derived, natural extracted, or synthetic-affects risk exposure to raw material shortages, geopolitical events, and tariff changes. In parallel, route-of-administration innovation influences formulation complexity and manufacturing footprints; inhalation, oral, parenteral, and topical modalities each present distinct technical and commercial trade-offs. Taken together, these themes create both opportunities and risks for manufacturers, contract development and manufacturing organizations, distributors, and veterinary pharmaceutical companies that are preparing for the next wave of product introductions.

Analysis of converging scientific, operational, and commercial forces that are remapping competitive dynamics and manufacturing approaches in animal health APIs

The animal health API landscape is undergoing a series of transformative shifts that are altering competitive boundaries and investment priorities. First, the therapeutic focus is gravitating toward targeted and species-specific interventions: biologics and peptides are expanding therapeutic reach for companion animals and high-value livestock applications, while antibiotic stewardship programs are driving reformulation and the development of non-antimicrobial alternatives. These scientific shifts necessitate new manufacturing capabilities, stronger cold-chain logistics, and closer collaboration between R&D and manufacturing teams.

Second, market participants are reassessing sourcing and manufacturing footprints in response to persistent supply chain disruptions and changing trade policies. This recalibration manifests as greater interest in regional supply network resilience, expanded use of contract manufacturing to flex capacity, and strategic stockpiling for critical intermediates. Simultaneously, sustainability has moved from a compliance checkbox to a competitive differentiator; companies are investing in greener chemistries, reduced solvent use, and waste minimization strategies that lower environmental impact while mitigating regulatory risk.

Third, digitalization and data-driven quality systems are reshaping operational effectiveness across development and manufacture. Companies increasingly deploy process analytical technology, predictive maintenance, and digital batch records to accelerate development cycles and enhance traceability. Regulatory authorities are also receptive to digital evidence demonstrating consistent quality, which creates a virtuous cycle: improved data fidelity reduces inspection friction and supports accelerated approvals. Finally, collaborative models-ranging from strategic alliances with academic centers to cross-industry consortia-are proliferating as organizations seek to share risk, access niche expertise, and accelerate the translation of novel modalities into commercial products. Collectively, these shifts are driving a more modular, resilient, and innovation-oriented industry architecture.

Examination of how recent tariff measures materially alter sourcing economics, supplier selection, and compliance burdens across the animal health API value chain

Recent tariff actions and trade policy adjustments have introduced an additional layer of complexity for actors engaged in the procurement, manufacture, and distribution of animal health APIs. Tariffs influence cost structures not only through direct import duties on finished APIs and intermediates but also by altering the economics of raw material sourcing, specialized reagents, and capital equipment required for biologic and peptide production. In response, organizations are revisiting supplier agreements, assessing nearshoring options, and reevaluating total landed cost models to preserve margins and continuity of supply.

Beyond cost implications, tariffs create behavioral shifts across the value chain. Manufacturers may prioritize domestic or regional suppliers for critical inputs, which can accelerate investment in local capacity and contract manufacturing partnerships. Conversely, some firms will choose to absorb additional duties to maintain relationships with trusted suppliers that offer superior quality or unique capabilities. For regulatory affairs teams, tariff-driven supplier changes often necessitate supplemental validation work and documentation updates to maintain compliance across jurisdictions, thereby increasing project timelines and administrative burden.

Strategically, the most resilient organizations adopt a layered approach to tariff exposure: they combine diversified sourcing, longer-term supply agreements with clear escalation clauses, and inventory optimization to smooth short-term shocks. Scenario planning and stress-testing of supplier networks reveal vulnerabilities and guide proactive mitigation measures, such as dual sourcing and investment in alternative synthesis routes for key intermediates. Moreover, organizations that invest in supply chain transparency and tariff impact analytics are better positioned to communicate price adjustments and risk mitigation strategies to commercial partners and regulators, preserving trust and market access despite policy uncertainty.

In-depth segmentation analysis linking animal type, therapeutic category, compound class, administration routes, and source origins to development and supply chain imperatives

Segmentation insights reveal where scientific innovation, regulatory focus, and commercial demand intersect to create differentiated opportunities across the animal health API landscape. Based on animal type, the market's demand drivers and product development priorities diverge significantly between aquaculture, companion animal, livestock, and poultry, with companion animals often leading adoption of cutting-edge biologics and aquaculture requiring formulations tolerant of aquatic environments. Based on product type, the therapeutic portfolio spans anti-inflammatories, antibiotics, antiparasitics, hormones, and vaccines, and each category presents distinct manufacturing and regulatory challenges; vaccines and antiparasitics typically demand robust cold-chain and stability strategies, whereas small-molecule antibiotics emphasize cost-effective synthetic routes and stewardship programs.

Based on compound type, biologics, peptides, and small molecules create three clear manufacturing pathways: biologics require cell-culture expertise and stringent aseptic environments; peptides benefit from advances in solid-phase synthesis and purification technologies; and small molecules continue to leverage mature chemical synthesis networks that prioritize yield and impurity control. Based on route of administration, inhalation, oral, parenteral, and topical routes impose different formulation constraints and delivery system investments. The inhalation modality further subdivides into aerosol, dry powder, and nebulization formats each with unique device and characterization demands, while the oral route includes bolus, granules, powder, and tablet formats that influence animal dosing behavior and palatability considerations. Parenteral routes-intramuscular, intravenous, and subcutaneous-demand sterility assurance and compatibility testing, and topical applications-dermatological, ophthalmic, and otic-require focused local-tolerability and stability studies.

Finally, based on source, fermentation derived, natural extracted, and synthetic origins affect supplier ecosystems and risk profiles: fermentation derived APIs can tie manufacturers to biotech supply chains and fermentation capacity constraints, natural extracts present variability and sustainability questions, and synthetic APIs lean on chemical precursor availability and process innovation. Understanding these segmentation layers in aggregate enables targeted investment, regulatory planning, and commercialization strategies that are appropriate for specific therapeutic targets and end-user contexts.

Strategic regional assessment that contrasts regulatory sophistication, manufacturing capabilities, and commercialization dynamics across global regions to inform localization

Regional dynamics play a pivotal role in shaping sourcing strategies, regulatory expectations, and commercial adoption across the animal health API sector. The Americas present a mature regulatory environment and advanced manufacturing capabilities, with strong demand for high-value therapeutics in companion and specialty livestock applications. Market participants in this region increasingly focus on biologics and peptide innovation, supported by robust clinical trial infrastructures and established cold-chain logistics, while also navigating supply chain security and tariff-driven cost considerations.

Europe, Middle East & Africa combines diverse regulatory regimes and market maturities, ranging from highly harmonized European standards to emerging regulatory frameworks in parts of the Middle East and Africa. This heterogeneity creates both challenges and opportunities: companies can leverage Europe's stringent quality expectations to validate premium products, while regionally tailored strategies are necessary to address affordability constraints and distribution complexities across varied geographies. Sustainability and antimicrobial stewardship are particularly prominent themes in this region, influencing both regulation and purchasing decisions.

Asia-Pacific is characterized by rapid demand growth, developing manufacturing capabilities, and a complex patchwork of regulatory pathways. The region is a critical node for chemical and biologic production, and many organizations rely on Asia-Pacific suppliers for key intermediates and API manufacturing. At the same time, rising domestic R&D investments and increasing regulatory sophistication are creating new centers of innovation and localized product development. Across all regions, companies that align manufacturing, regulatory, and commercial strategies to regional characteristics gain competitive advantage and reduce market-entry friction.

Evaluation of how corporate strategies, capability specialization, and collaborative models are reshaping competitive advantages and partnership patterns in the API ecosystem

Company-level dynamics are being reshaped by a combination of strategic investment, capability specialization, and collaborative linkages across the value chain. Leading firms and specialized contract development and manufacturing organizations are differentiating through focused capability stacks-such as biologics process development, peptide synthesis scale-up, or complex inhalation device integration-to serve niche clinical and commercial needs. These capability clusters create higher barriers to entry for commodity players while opening partnership opportunities for firms that lack in-house expertise.

At the same time, mergers, strategic alliances, and technology licensing are common mechanisms for companies to accelerate capability acquisition and market entry without the full burden of capital investment. Such arrangements frequently involve cross-border collaboration and create implications for intellectual property management, regulatory filings, and cross-jurisdictional quality systems. Talent and technical know-how remain limiting factors in advanced modalities; companies that invest in workforce development and knowledge transfer programs secure a reproducible advantage in complex API production.

Finally, firms that proactively embed sustainability, traceability, and digital quality systems into their operations increase their appeal to large purchasers and regulatory stakeholders. Demonstrable commitments to greener chemistries, lower carbon footprints, and transparent sourcing strengthen commercial positioning and can accelerate approvals in markets prioritizing environmental stewardship. Collectively, these company-level moves determine who can deliver high-complexity APIs reliably and cost-effectively into an increasingly demanding market.

Actionable playbook for executives to enhance resilience, accelerate biologics and peptide capabilities, and optimize sourcing and regulatory engagement in animal health APIs

Industry leaders should pursue a pragmatic combination of strategic investments and operational adjustments to convert risk into opportunity. First, diversify supplier networks and build regional redundancy for critical intermediates and specialized reagents to reduce exposure to single points of failure and tariff volatility. Investing in dual sourcing and nearshoring for priority inputs supports continuity while enabling faster regulatory response when supplier changes are required. Second, allocate capital toward biologics and peptide manufacturing capabilities where scientific and commercial signals indicate durable demand; paired with strategic partnerships, this reduces time-to-market and leverages external expertise without overextending internal resources.

Third, prioritize route-of-administration innovation that aligns with end-user preferences and administration feasibility; for companion animals, palatability and easy-to-administer formats are often decisive, whereas for livestock and poultry, dosing efficiency and cost per treatment dominate decisions. Fourth, enhance regulatory engagement early and often: share development plans with regulatory bodies, pursue parallel consultations across jurisdictions when feasible, and standardize documentation to reduce approval timelines and inspection risk. Fifth, embed sustainability in procurement and process design through greener chemistry choices, waste reduction programs, and transparent sourcing protocols that can be evidenced to buyers and regulators.

Finally, operationalize data and digital solutions to improve traceability, predictive maintenance, and quality assurance. Implementing process analytical technologies and robust batch record systems reduces variability and supports faster scale-up. Scenario planning and tariff-impact modeling should be integrated into commercial and procurement decision processes so that price adjustments and sourcing shifts can be made proactively and communicated clearly to stakeholders. Taken together, these steps help create a resilient, innovation-ready organization capable of navigating emerging policy and market challenges.

Transparent research methodology combining primary interviews, secondary literature, and triangulated evidence to produce robust, actionable industry insights

The research underpinning this analysis combines primary qualitative insights with comprehensive secondary data synthesis to ensure robustness and relevance. Primary inputs include structured interviews with industry stakeholders such as formulation scientists, manufacturing leaders, procurement professionals, veterinary clinical experts, and regulatory affairs specialists. These conversations provided frontline perspectives on supply chain constraints, technological adoption, and unmet therapeutic needs across different animal types and administration routes. Where possible, cross-validation with multiple stakeholder groups was used to reconcile differing views and identify persistent patterns.

Secondary research encompassed authoritative scientific literature, regulatory guidance documents, patent filings, and public disclosures of manufacturing investments and partnerships. Information from trade publications and conference proceedings supplemented these sources to capture recent product launches, technology demonstrations, and collaborative announcements. Data triangulation ensured that conclusions were not reliant on any single source and allowed for the identification of convergent trends across independent inputs.

Methodological rigor included clear inclusion criteria for sources, transparent documentation of interview protocols, and quality checks on interpretive analysis. Limitations are acknowledged: rapidly evolving policies and commercial arrangements may change the competitive landscape between updates, and access constraints limit the granularity of some proprietary supply agreements. To mitigate these factors, the methodology emphasizes scenario-based insights and identifies leading indicators that stakeholders can monitor to update their strategic assessments in real time.

Concise synthesis of the strategic imperatives and operational priorities that will determine success in the evolving animal health API market

The cumulative picture is one of an industry in transition, where scientific advancements, regulatory evolution, and supply chain realities intersect to redefine strategic priorities. Biologics and peptides are reshaping therapeutic possibilities, whereas small molecules retain a central role in core indications. Route-of-administration choices and source origins materially influence manufacturing complexity, regulatory requirements, and commercial uptake, and they must be considered as integral elements of product strategy rather than afterthoughts.

Regional dynamics and tariff environments further complicate planning, making supply chain transparency and diversified sourcing essential components of resilience. Companies that invest in specialized capabilities, embrace collaborative models for capacity and knowledge sharing, and embed sustainability and digital quality systems into their operations will be best positioned to capture the upside of innovation while controlling downside risk. Ultimately, a disciplined, multidimensional approach that links R&D, manufacturing, procurement, regulatory, and commercial teams yields the strongest foundation for long-term success in the animal health API sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Health Active Pharmaceutical Ingredients Market, by Animal Type

  • 8.1. Aquaculture
  • 8.2. Companion Animal
  • 8.3. Livestock
  • 8.4. Poultry

9. Animal Health Active Pharmaceutical Ingredients Market, by Product Type

  • 9.1. Anti Inflammatories
  • 9.2. Antibiotics
  • 9.3. Antiparasitics
  • 9.4. Hormones
  • 9.5. Vaccines

10. Animal Health Active Pharmaceutical Ingredients Market, by Compound Type

  • 10.1. Biologic
  • 10.2. Peptide
  • 10.3. Small Molecule

11. Animal Health Active Pharmaceutical Ingredients Market, by Source

  • 11.1. Fermentation Derived
  • 11.2. Natural Extracted
  • 11.3. Synthetic

12. Animal Health Active Pharmaceutical Ingredients Market, by Application

  • 12.1. Infectious Disease Management
  • 12.2. Pain Management
  • 12.3. Parasitic Control
  • 12.4. Immune Support
  • 12.5. Reproductive Health
  • 12.6. Chronic Disease Treatment

13. Animal Health Active Pharmaceutical Ingredients Market, by End-User

  • 13.1. Animal Feed Manufacturers
  • 13.2. Pharmaceutical Companies
  • 13.3. Contract Manufacturing Organizations (CMOs)

14. Animal Health Active Pharmaceutical Ingredients Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Animal Health Active Pharmaceutical Ingredients Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Animal Health Active Pharmaceutical Ingredients Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Animal Health Active Pharmaceutical Ingredients Market

18. China Animal Health Active Pharmaceutical Ingredients Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Alivira Animal Health Limited
  • 19.6. Ashish Life Science Pvt. Ltd.
  • 19.7. Aurobindo Pharma Ltd.
  • 19.8. Boehringer Ingelheim International GmbH
  • 19.9. Ceva Sante Animale
  • 19.10. Cipla Ltd.
  • 19.11. Elanco Animal Health Incorporated
  • 19.12. Hikal Ltd.
  • 19.13. Huvepharma Inc.
  • 19.14. Karishma Pharma Pvt. Ltd.
  • 19.15. Menon Animal Health
  • 19.16. Merck & Co., Inc.
  • 19.17. NGL Fine-Chem Ltd.
  • 19.18. Phibro Animal Health Corporation
  • 19.19. Ridgeway Biologicals Ltd.
  • 19.20. Sequent Scientific Ltd.
  • 19.21. Vetoquinol S.A.
  • 19.22. Virbac SA
  • 19.23. Zoetis Inc.
  • 19.24. Zydus Animal Health and Investments Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPANION ANIMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPANION ANIMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPANION ANIMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTI INFLAMMATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTI INFLAMMATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTI INFLAMMATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIPARASITICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANTIPARASITICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOLOGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY FERMENTATION DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY FERMENTATION DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY FERMENTATION DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NATURAL EXTRACTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NATURAL EXTRACTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY NATURAL EXTRACTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INFECTIOUS DISEASE MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INFECTIOUS DISEASE MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INFECTIOUS DISEASE MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARASITIC CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARASITIC CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PARASITIC CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY IMMUNE SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY IMMUNE SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY IMMUNE SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CHRONIC DISEASE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CHRONIC DISEASE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CHRONIC DISEASE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL FEED MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL FEED MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL FEED MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS (CMOS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS (CMOS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS (CMOS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 150. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 166. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 171. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)